AstraZeneca has filed a patent for methods of treating cancer by administering an antibody-drug conjugate (ADC), a cytotoxic agent, and an additional agent, which can be a PARP1 inhibitor or an ATR inhibitor. The patent also includes kits containing these components. The patent claims a specific amino acid sequence for the antibody or antigen binding fragment of the ADC. GlobalData’s report on AstraZeneca gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca's grant share as of September 2023 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
The patent filed is for a method of treating cancer
A recently filed patent (Publication Number: US20230310636A1) describes a method for treating cancer in human subjects. The method involves administering an antibody-drug conjugate (ADC) to the patient, which consists of an antibody or antigen binding fragment that binds to a B7-H4 polypeptide. The ADC also includes a cleavable linker and a cytotoxic agent. In addition to the ADC, an additional agent is administered, which can be a PARP1 inhibitor or an ATR inhibitor.
The patent claims cover various aspects of the method, including the specific amino acid sequences of the antibody or antigen binding fragment, the cleavable linker, and the cytotoxic agent. The method can be used to treat different types of cancer, such as ovarian cancer, breast cancer, pancreatic cancer, prostate cancer, hematological cancer, endometrial cancer, cholangiocarcinoma, NSCLC (squamous and/or adenocarcinoma), gastrointestinal cancer (gastric cancer and colorectal cancer), and lung cancer. It is particularly effective for breast cancer, including hormone receptor-positive (HR+) breast cancer, human epidermal growth factor receptor 2 positive (HER2+) breast cancer, and triple negative breast cancer (TNBC).
The patent also mentions that the method can be used for treating homologous recombination deficient (HRD) cancer, which includes cancer cells with mutations in HRD genes such as BRCA1, BRCA2, ATM, BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L.
The ADC in the method has a drug to antibody ratio (DAR) between about 1 and about 8. The patent also includes a kit comprising the ADC and the additional agent for ease of administration.
Overall, this patent describes a method for treating cancer using an antibody-drug conjugate and an additional agent, which can be a PARP1 inhibitor or an ATR inhibitor. The method is applicable to various types of cancer, including breast cancer and HRD cancer. The specific amino acid sequences of the antibody or antigen binding fragment, the cleavable linker, and
To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
